- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04414189
Clinical Validation of HostDx Sepsis™ on NanoString; a Prospective Observational Validation Trial
7. desember 2021 oppdatert av: Inflammatix
This study will analyze HostDx Sepsis results from whole blood samples collected from patients with suspected sepsis or at risk for sepsis in the surgical ICU
Studieoversikt
Studietype
Observasjonsmessig
Registrering (Faktiske)
200
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Florida
-
Gainesville, Florida, Forente stater, 32610
- University of Florida College of Medicine
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Subjects admitted to the surgical ICU with suspected sepsis or at high risk for subsequent sepsis onset.
Beskrivelse
Inclusion Criteria:
Arm A
- Age > 18 years
- Suspected sepsis at the time of admission to the ICU
- Direct admission from the ED to the ICU with suspected/proven sepsis.
- Post-operative ICU admission after sepsis source control procedure
- Inpatients admitted to the ICU from the ward with suspected sepsis onset.
- Able to provide subject/proxy informed consent within 96h
Arm B
- Age > 18 years
- No suspicion of sepsis at the time of admission to the ICU but at high risk for subsequent sepsis onset
- Non-trauma admission from the ED to the ICU
- Post-operative ICU admission
- Severe trauma admission from the ED (injury severity score >15, hemorrhagic shock, severe traumatic brain injury, and or severe chest trauma)
- Inpatients admitted to the ICU from the ward for decompensation not initially suspected to be secondary to sepsis.
- Able to provide subject/proxy informed consent within 96h
Exclusion Criteria:
- Pre- or post-transplant patients
- Patients admitted solely for airway monitoring, or vascular/flap check monitoring
- Previous diagnosis of sepsis on index hospitalization.
- Unable to provide informed consent within 96h
- Previously enrolled in the present study.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Arm A
Patients with suspected sepsis at the time of admission to the ICU
|
Blood collection for mRNA analysis
|
|
Arm B
Patients not currently suspected but at high risk for sepsis.
|
Blood collection for mRNA analysis
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Validate the diagnostic accuracy of HostDx Sepsis in a cohort of 360 hospitalized patients enrolled at time of suspicion of sepsis or at high risk for developing sepsis.
Tidsramme: Time to enroll 360 subjects, process samples, and complete the follow-up, an average of 1 year
|
Percentage of correctly identified patients with bacterial and/or viral infections using HostDx Sepsis compared to clinical adjudications using routine clinical, laboratory, and other findings
|
Time to enroll 360 subjects, process samples, and complete the follow-up, an average of 1 year
|
|
Validate the prognostic accuracy of HostDx Sepsis in a cohort of 360 hospitalized patients enrolled at time of suspicion of sepsis or at high risk for developing sepsis.
Tidsramme: Time to enroll 360 subjects, process samples, and complete the follow-up, an average of 1 year
|
Percentage of patients with correctly predicted outcomes using HostDx Sepsis (7-day organ support), and agreement between observed likelihood ratios and target likelihood ratios for the interpretation bands in HostDx Sepsis
|
Time to enroll 360 subjects, process samples, and complete the follow-up, an average of 1 year
|
|
Validate the prognostic accuracy of HostDx Sepsis in a cohort of 360 hospitalized patients enrolled at time of suspicion of sepsis or at high risk for developing sepsis.
Tidsramme: Time to enroll 360 subjects, process samples, and complete the follow-up, an average of 1 year
|
Percentage of patients with correctly predicted outcomes using HostDx Sepsis (CCI), and agreement between observed likelihood ratios and target likelihood ratios for the interpretation bands in HostDx Sepsis
|
Time to enroll 360 subjects, process samples, and complete the follow-up, an average of 1 year
|
|
Validate the prognostic accuracy of HostDx Sepsis in a cohort of 360 hospitalized patients enrolled at time of suspicion of sepsis or at high risk for developing sepsis.
Tidsramme: Time to enroll 360 subjects, process samples, and complete the follow-up, an average of 1 year
|
Percentage of patients with correctly predicted outcomes using HostDx Sepsis (30-day mortality), and agreement between observed likelihood ratios and target likelihood ratios for the interpretation bands in HostDx Sepsis
|
Time to enroll 360 subjects, process samples, and complete the follow-up, an average of 1 year
|
|
Validate the prognostic accuracy of HostDx Sepsis in a cohort of 360 hospitalized patients enrolled at time of suspicion of sepsis or at high risk for developing sepsis.
Tidsramme: Time to enroll 360 subjects, process samples, and complete the follow-up, an average of 1 year
|
Percentage of patients with correctly predicted outcomes using HostDx Sepsis (90-day mortality), and agreement between observed likelihood ratios and target likelihood ratios for the interpretation bands in HostDx Sepsis
|
Time to enroll 360 subjects, process samples, and complete the follow-up, an average of 1 year
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
7. juni 2020
Primær fullføring (Faktiske)
21. juli 2021
Studiet fullført (Faktiske)
19. oktober 2021
Datoer for studieregistrering
Først innsendt
22. mai 2020
Først innsendt som oppfylte QC-kriteriene
29. mai 2020
Først lagt ut (Faktiske)
4. juni 2020
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
22. desember 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
7. desember 2021
Sist bekreftet
1. desember 2021
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- INF-06
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .